Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 5/20 | 0.45 |
| ▸ | PPARG | P37231 | 4/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25711918 | 1.00 | ATM (0.50) | ATMPPARAPPARGMTNR1AMTNR1B | |
| SCHEMBL2945955 | 0.86 | ATM (0.50) | ATMPPARAPPARGMTNR1AMTNR1B | |
| SCHEMBL28499654 | 0.85 | ATM (0.49) | ATMPPARAPPARGMTNR1AMTNR1B | |
| SCHEMBL22409416 | 0.85 | PLA2G10 (0.50) | ATMPPARAPPARGMTNR1AMTNR1B | |
| SCHEMBL22409417 | 0.85 | PLA2G10 (0.50) | ATMPPARAPPARGMTNR1AMTNR1B | |
| SCHEMBL22203002 | 0.84 | ATM (0.48) | ATMPPARAPPARGMTNR1AMTNR1B | |
| SCHEMBL22202987 | 0.84 | ATM (0.48) | ATMPPARAPPARGMTNR1AMTNR1B | |
| SCHEMBL7321063 | 0.84 | ATM (0.64) | ATMPPARAPPARGPPARDSYK | |
| SCHEMBL22409489 | 0.84 | ATM (0.48) | ATMPPARAPPARGMTNR1AMTNR1B | |
| SCHEMBL19014888 | 0.84 | ATM (0.48) | ATMPPARAPPARGMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4598905-A2 | CEREBLON-RECRUITING BCL-XL/BCL-2 DUAL DEGRADERS | University of Florida Research Foundation, Incorporated (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-3743069-B1 | BCL-2 PROTEINS DEGRADERS FOR CANCER TREATMENT | BIOVENTURES LLC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20240408085-A1 | COMPOUND FOR DEGRADATION OF BCL-2 FAMILY PROTEINS AND MEDICAL APPLICATION THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-12-12 | — | — | US | disclosed |
| EP-4444717-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | University of Florida Research Foundation, Incorporated (US) | 2024-10-16 | — | — | EP | disclosed |
| US-12118414-B2 | BCL-2 proteins degraders for cancer treatment | BIOVENTURES, LLC (US) | 2024-10-15 | — | — | US | disclosed |
| WO-2024179577-A1 | PHARMACEUTICAL COMPOSITION FOR BCL-2 FAMILY PROTEIN DEGRADATION AGENT | 西藏海思科制药有限公司 | 2024-09-06 | — | — | WO | disclosed |
| EP-4401729-A1 | BCL-XL DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20210070788-A1 | Phospholidines that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer | UNITY BIOTECHNOLOGY, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20200331905-A1 | Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof | BIOVENTURES, LLC | 2020-10-22 | — | — | US | disclosed |
| US-10807977-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BIOVENTURES, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | UNITY BIOTECHNOLOGY, INC. | 2020-09-17 | — | — | US | disclosed |
| US-10745429-B2 | Phospholidines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | UNITY BIOTECHNOLOGY, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| WO-2020140956-A1 | PROCESS FOR PREPARING SULFONAMIDE COMPOUNDS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-07-09 | — | — | WO | disclosed |
| US-20190330250-A1 | Phospholidines that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated By Senescent Cells and for Treating Cancer | UNITY BIOTECHNOLOGY, INC. | 2019-10-31 | — | — | US | disclosed |
| US-20190135801-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-05-09 | — | — | US | disclosed |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-02-21 | — | — | US | disclosed |
| WO-2017101851-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | UNITY BIOTECHNOLOGY, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408085-A1 | COMPOUND FOR DEGRADATION OF BCL-2 FAMILY PROTEINS AND MEDICAL APPLICATION THEREOF | BCL2L11, BCL2L2, BCL3 | ATM 3592/4885PPARA 3002/4885PPARG 2134/4885 |
| US-20210070788-A1 | Phospholidines that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer | BCL2, BAX, BCL9 | ATM 539/4885PPARA 317/4885PPARG 288/4885 |
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | BCL2, BCL2L2, BCL2L1 | ATM 2205/4885PPARA 3342/4885PPARG 2079/4885 |
| US-12118414-B2 | BCL-2 proteins degraders for cancer treatment | BCL2, BCL2L1, BCL2L2 | ATM 1628/4885PPARA 3739/4885PPARG 2832/4885 |
| US-20190330250-A1 | Phospholidines that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated By Senescent Cells and for Treating Cancer | BCL2, BAX, BCL9 | ATM 539/4885PPARA 317/4885PPARG 288/4885 |
| US-20200331905-A1 | Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof | BCL2, BAX, BCL2L1 | ATM 941/4885PPARA 1903/4885PPARG 724/4885 |
| US-10745429-B2 | Phospholidines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | BCL2, BCL9, BAX | ATM 609/4885PPARA 354/4885PPARG 277/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | ATM 3487/4885PPARA 2731/4885PPARG 1614/4885 |
| US-20190135801-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BCL2, BAX, BCL2L1 | ATM 941/4885PPARA 1903/4885PPARG 724/4885 |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | ACAT1, ARSA, GLA | ATM 404/4885PPARA 204/4885PPARG 132/4885 |
| US-10807977-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BCL2, BAX, BCL2L1 | ATM 941/4885PPARA 1903/4885PPARG 724/4885 |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | TP53, MCL1, LIMS1 | ATM 327/4885PPARA 2294/4885PPARG 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.